|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q55609397
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000036.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q55609397
|
|
024
|
|
|
‡a
0000-0002-2028-5723
‡2
orcid
|
|
024
|
|
|
‡a
35519059400
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q55609397
|
|
046
|
|
|
‡f
19450000
|
|
100
|
0 |
|
‡a
Rudy J. Richardson
‡c
researcher
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Rudy J Richardson
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's Absence of sensory neuropathy among workers with occupational exposure to chlorpyrifos.
|
|
670
|
|
|
‡a
Author's Aging of mipafox-inhibited human acetylcholinesterase proceeds by displacement of both isopropylamine groups to yield a phosphate adduct.
|
|
670
|
|
|
‡a
Author's Biomarkers of drug-induced vascular injury.
|
|
670
|
|
|
‡a
Author's Biosensor analysis of blood esterases for organophosphorus compounds exposure assessment: approaches to simultaneous determination of several esterases
|
|
670
|
|
|
‡a
Author's Biosensor detection of neuropathy target esterase in whole blood as a biomarker of exposure to neuropathic organophosphorus compounds
|
|
670
|
|
|
‡a
Author's Chlorpyrifos: assessment of potential for delayed neurotoxicity by repeated dosing in adult hens with monitoring of brain acetylcholinesterase, brain and lymphocyte neurotoxic esterase, and plasma butyrylcholinesterase activities.
|
|
670
|
|
|
‡a
Author's Chlorpyrifos exposure and biological monitoring among manufacturing workers
|
|
670
|
|
|
‡a
Author's Common mechanism of toxicity: a case study of organophosphorus pesticides.
|
|
670
|
|
|
‡a
Author's Conjugates of methylene blue with γ-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases
|
|
670
|
|
|
‡a
Author's Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties.
|
|
670
|
|
|
‡a
Author's Dose-effect analyses of occupational chlorpyrifos exposure and peripheral nerve electrophysiology.
|
|
670
|
|
|
‡a
Author's Effects of occupational exposure to chlorpyrifos on neuropsychological function: a prospective longitudinal study.
|
|
670
|
|
|
‡a
Author's Esterase profile of O-phosphorylated ethyltrifluorolactates in prediction of their therapeutic and toxic effects
|
|
670
|
|
|
‡a
Author's Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury
|
|
670
|
|
|
‡a
Author's Evidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury.
|
|
670
|
|
|
‡a
Author's Fluorinated alpha-aminophosphonates--a new type of irreversible inhibitors of serine hydrolases.
|
|
670
|
|
|
‡a
Author's Further studies toward a mouse model for biochemical assessment of neuropathic potential of organophosphorus compounds.
|
|
670
|
|
|
‡a
Author's Identification of butyrylcholinesterase adducts after inhibition with isomalathion using mass spectrometry: difference in mechanism between (1R)- and (1S)-stereoisomers.
|
|
670
|
|
|
‡a
Author's Improved electrochemical analysis of neuropathy target esterase activity by a tyrosinase carbon paste electrode modified by 1-methoxyphenazine methosulfate.
|
|
670
|
|
|
‡a
Author's Inhibition of hen brain acetylcholinesterase and neurotoxic esterase by chlorpyrifos in vivo and kinetics of inhibition by chlorpyrifos oxon in vitro: Application to assessment of neuropathic risk*
|
|
670
|
|
|
‡a
Author's Inhibition of neurotoxic esterase in vitro by novel carbamates.
|
|
670
|
|
|
‡a
Author's Kinetics and mechanism of inhibition of serine esterases by fluorinated carbethoxy 1-aminophosphonates.
|
|
670
|
|
|
‡a
Author's Mechanism of aging of mipafox-inhibited butyrylcholinesterase
|
|
670
|
|
|
‡a
Author's Modeling the tertiary structure of the patatin domain of neuropathy target esterase.
|
|
670
|
|
|
‡a
Author's Motor neuron disease due to neuropathy target esterase mutation: enzyme analysis of fibroblasts from human subjects yields insights into pathogenesis.
|
|
670
|
|
|
‡a
Author's Neuropathy target esterase gene mutations cause motor neuron disease
|
|
670
|
|
|
‡a
Author's Neuropathy target esterase (NTE): overview and future.
|
|
670
|
|
|
‡a
Author's New Multifunctional Agents Based on Conjugates of 4-Amino-2,3-polymethylenequinoline and Butylated Hydroxytoluene for Alzheimer's Disease Treatment
|
|
670
|
|
|
‡a
Author's Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers.
|
|
670
|
|
|
‡a
Author's Phenylmethanesulfonyl fluoride elicits and intensifies the clinical expression of neuropathic insults
|
|
670
|
|
|
‡a
Author's Potentiation of organophosphorus compound-induced delayed neurotoxicity
|
|
670
|
|
|
‡a
Author's Potentiation of organophosphorus compound-induced delayed neurotoxicity (OPIDN) in the central and peripheral nervous system of the adult hen: distribution of axonal lesions
|
|
670
|
|
|
‡a
Author's Probing the active sites of butyrylcholinesterase and cholesterol esterase with isomalathion: conserved stereoselective inactivation of serine hydrolases structurally related to acetylcholinesterase.
|
|
670
|
|
|
‡a
Author's Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
|
|
670
|
|
|
‡a
Author's Quantitative structure-activity relationships predict the delayed neurotoxicity potential of a series of O-alkyl-O-methylchloroformimino phenylphosphonates.
|
|
670
|
|
|
‡a
Author's Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase.
|
|
670
|
|
|
‡a
Author's Relative potencies of the four stereoisomers of isomalathion for inhibition of hen brain acetylcholinesterase and neurotoxic esterase in vitro.
|
|
670
|
|
|
‡a
Author's Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
|
|
670
|
|
|
‡a
Author's Tethered lipid bilayers on electrolessly deposited gold for bioelectronic applications.
|
|
670
|
|
|
‡a
Author's The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
|
|
670
|
|
|
‡a
Author's The effects of occupational exposure to chlorpyrifos on the neurologic examination of central nervous system function: a prospective cohort study.
|
|
670
|
|
|
‡a
Author's The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: a prospective cohort study
|
|
670
|
|
|
‡a
Author's Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
|
|
670
|
|
|
‡a
Author's Uptake of Mercury and Mercury-Amino Acid Complexes by Rat Renal Cortex Slices
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/DNB|1129184250
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/77673803
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/LC|n 82208509
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/SUDOC|260294500
|
|
909
|
|
|
‡a
(scopus) 35519059400
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000220285723
‡9
1
|
|
919
|
|
|
‡a
relativeinhibitorypotenciesofchlorpyrifosoxonchlorpyrifosmethyloxonandmipafoxforacetylcholinesteraseversusneuropathytargetesterase
‡A
Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase.
‡9
1
|
|
919
|
|
|
‡a
uptakeofmercuryandmercuryaminoacidcomplexesbyratrenalcortexslices
‡A
Uptake of Mercury and Mercury-Amino Acid Complexes by Rat Renal Cortex Slices
‡9
1
|
|
919
|
|
|
‡a
effectofthrombinona6hydroxydopaminemodelofparkinsonsdiseasedependsontiming
‡A
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
‡9
1
|
|
919
|
|
|
‡a
thrombinpreconditioningprovidesprotectionina6hydroxydopamineparkinsonsdiseasemodel
‡A
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
‡9
1
|
|
919
|
|
|
‡a
effectsofoccupationalexposuretochlorpyrifosontheperipheralnervoussystemaprospectivecohortstudy
‡A
The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: a prospective cohort study
‡9
1
|
|
919
|
|
|
‡a
effectsofoccupationalexposuretochlorpyrifosontheneurologicexaminationofcentralnervoussystemfunctionaprospectivecohortstudy
‡A
The effects of occupational exposure to chlorpyrifos on the neurologic examination of central nervous system function: a prospective cohort study.
‡9
1
|
|
919
|
|
|
‡a
tetheredlipidbilayersonelectrolesslydepositedgoldforbioelectronicapplications
‡A
Tethered lipid bilayers on electrolessly deposited gold for bioelectronic applications.
‡9
1
|
|
919
|
|
|
‡a
synthesisoforganophosphateswithfluorinecontainingleavinggroupsasserineesteraseinhibitorswithpotentialforalzheimerdiseasetherapeutics
‡A
Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
‡9
1
|
|
919
|
|
|
‡a
relativepotenciesofthe4stereoisomersofisomalathionforinhibitionofhenbrainacetylcholinesteraseandneurotoxicesteraseinvitro
‡A
Relative potencies of the four stereoisomers of isomalathion for inhibition of hen brain acetylcholinesterase and neurotoxic esterase in vitro.
‡9
1
|
|
919
|
|
|
‡a
quantitativestructureactivityrelationshipspredictthedelayedneurotoxicitypotentialofaseriesofoalkylomethylchloroformiminophenylphosphonates
‡A
Quantitative structure-activity relationships predict the delayed neurotoxicity potential of a series of O-alkyl-O-methylchloroformimino phenylphosphonates.
‡9
1
|
|
919
|
|
|
‡a
proteaseactivatedreceptor1mediatesprotectionelicitedbythrombinpreconditioninginarat6hydroxydopaminemodelofparkinsonsdisease
‡A
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
‡9
1
|
|
919
|
|
|
‡a
probingtheactivesitesofbutyrylcholinesteraseandcholesterolesterasewithisomalathionconservedstereoselectiveinactivationofserinehydrolasesstructurallyrelatedtoacetylcholinesterase
‡A
Probing the active sites of butyrylcholinesterase and cholesterol esterase with isomalathion: conserved stereoselective inactivation of serine hydrolases structurally related to acetylcholinesterase.
‡9
1
|
|
919
|
|
|
‡a
potentiationoforganophosphoruscompoundinduceddelayedneurotoxicityopidninthecentralandperipheralnervoussystemoftheadulthendistributionofaxonallesions
‡A
Potentiation of organophosphorus compound-induced delayed neurotoxicity (OPIDN) in the central and peripheral nervous system of the adult hen: distribution of axonal lesions
‡9
1
|
|
919
|
|
|
‡a
potentiationoforganophosphoruscompoundinduceddelayedneurotoxicity
‡A
Potentiation of organophosphorus compound-induced delayed neurotoxicity
‡9
1
|
|
919
|
|
|
‡a
phenylmethanesulfonylfluorideelicitsandintensifiestheclinicalexpressionofneuropathicinsults
‡A
Phenylmethanesulfonyl fluoride elicits and intensifies the clinical expression of neuropathic insults
‡9
1
|
|
919
|
|
|
‡a
paraoxonasestatusandplasmabutyrylcholinesteraseactivityinchlorpyrifosmanufacturingworkers
‡A
Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers.
‡9
1
|
|
919
|
|
|
‡a
newmultifunctionalagentsbasedonconjugatesof4amino23polymethylenequinolineandbutylatedhydroxytolueneforalzheimersdiseasetreatment
‡A
New Multifunctional Agents Based on Conjugates of 4-Amino-2,3-polymethylenequinoline and Butylated Hydroxytoluene for Alzheimer's Disease Treatment
‡9
1
|
|
919
|
|
|
‡a
neuropathytargetesterasenteoverviewandfuture
‡A
Neuropathy target esterase (NTE): overview and future.
‡9
1
|
|
919
|
|
|
‡a
neuropathytargetesterasegenemutationscausemotorneurondisease
‡A
Neuropathy target esterase gene mutations cause motor neuron disease
‡9
1
|
|
919
|
|
|
‡a
motorneurondiseaseduetoneuropathytargetesterasemutationenzymeanalysisoffibroblastsfromhumansubjectsyieldsinsightsintopathogenesis
‡A
Motor neuron disease due to neuropathy target esterase mutation: enzyme analysis of fibroblasts from human subjects yields insights into pathogenesis.
‡9
1
|
|
919
|
|
|
‡a
modelingthetertiarystructureofthepatatindomainofneuropathytargetesterase
‡A
Modeling the tertiary structure of the patatin domain of neuropathy target esterase.
‡9
1
|
|
919
|
|
|
‡a
mechanismofagingofmipafoxinhibitedbutyrylcholinesterase
‡A
Mechanism of aging of mipafox-inhibited butyrylcholinesterase
‡9
1
|
|
919
|
|
|
‡a
kineticsandmechanismofinhibitionofserineesterasesbyfluorinatedcarbethoxy1aminophosphonates
‡A
Kinetics and mechanism of inhibition of serine esterases by fluorinated carbethoxy 1-aminophosphonates.
‡9
1
|
|
919
|
|
|
‡a
inhibitionofneurotoxicesteraseinvitrobynovelcarbamates
‡A
Inhibition of neurotoxic esterase in vitro by novel carbamates.
‡9
1
|
|
919
|
|
|
‡a
inhibitionofhenbrainacetylcholinesteraseandneurotoxicesterasebychlorpyrifosinvivoandkineticsofinhibitionbychlorpyrifosoxoninvitroapplicationtoassessmentofneuropathicrisk
‡A
Inhibition of hen brain acetylcholinesterase and neurotoxic esterase by chlorpyrifos in vivo and kinetics of inhibition by chlorpyrifos oxon in vitro: Application to assessment of neuropathic risk*
‡9
1
|
|
919
|
|
|
‡a
improvedelectrochemicalanalysisofneuropathytargetesteraseactivitybyatyrosinasecarbonpasteelectrodemodifiedby1methoxyphenazinemethosulfate
‡A
Improved electrochemical analysis of neuropathy target esterase activity by a tyrosinase carbon paste electrode modified by 1-methoxyphenazine methosulfate.
‡9
1
|
|
919
|
|
|
‡a
identificationofbutyrylcholinesteraseadductsafterinhibitionwithisomalathionusingmassspectrometrydifferenceinmechanismbetween1rand1sstereoisomers
‡A
Identification of butyrylcholinesterase adducts after inhibition with isomalathion using mass spectrometry: difference in mechanism between (1R)- and (1S)-stereoisomers.
‡9
1
|
|
919
|
|
|
‡a
furtherstudiestowardamousemodelforbiochemicalassessmentofneuropathicpotentialoforganophosphoruscompounds
‡A
Further studies toward a mouse model for biochemical assessment of neuropathic potential of organophosphorus compounds.
‡9
1
|
|
919
|
|
|
‡a
fluorinatedalphaaminophosphonatesanewtypeofirreversibleinhibitorsofserinehydrolases
‡A
Fluorinated alpha-aminophosphonates--a new type of irreversible inhibitors of serine hydrolases.
‡9
1
|
|
919
|
|
|
‡a
evidenceforthenitricoxidepathwayasapotentialmodeofactioninfenoldopaminducedvascularinjury
‡A
Evidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury.
‡9
1
|
|
919
|
|
|
‡a
evaluationofvonwillebrandfactorandvonwillebrandfactorpropeptideinmodelsofvascularendothelialcellactivationperturbationandorinjury
‡A
Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury
‡9
1
|
|
919
|
|
|
‡a
esteraseprofileofophosphorylatedethyltrifluorolactatesinpredictionoftheirtherapeuticandtoxiceffects
‡A
Esterase profile of O-phosphorylated ethyltrifluorolactates in prediction of their therapeutic and toxic effects
‡9
1
|
|
919
|
|
|
‡a
effectsofoccupationalexposuretochlorpyrifosonneuropsychologicalfunctionaprospectivelongitudinalstudy
‡A
Effects of occupational exposure to chlorpyrifos on neuropsychological function: a prospective longitudinal study.
‡9
1
|
|
919
|
|
|
‡a
doseeffectanalysesofoccupationalchlorpyrifosexposureandperipheralnerveelectrophysiology
‡A
Dose-effect analyses of occupational chlorpyrifos exposure and peripheral nerve electrophysiology.
‡9
1
|
|
919
|
|
|
‡a
constructsofhumanneuropathytargetesterasecatalyticdomaincontainingmutationsrelatedtomotorneurondiseasehavealteredenzymaticproperties
‡A
Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties.
‡9
1
|
|
919
|
|
|
‡a
conjugatesofmethylenebluewithγcarbolinederivativesasnewmultifunctionalagentsforthetreatmentofneurodegenerativediseases
‡A
Conjugates of methylene blue with γ-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases
‡9
1
|
|
919
|
|
|
‡a
commonmechanismoftoxicityacasestudyoforganophosphoruspesticides
‡A
Common mechanism of toxicity: a case study of organophosphorus pesticides.
‡9
1
|
|
919
|
|
|
‡a
chlorpyrifosexposureandbiologicalmonitoringamongmanufacturingworkers
‡A
Chlorpyrifos exposure and biological monitoring among manufacturing workers
‡9
1
|
|
919
|
|
|
‡a
chlorpyrifosassessmentofpotentialfordelayedneurotoxicitybyrepeateddosinginadulthenswithmonitoringofbrainacetylcholinesterasebrainandlymphocyteneurotoxicesteraseandplasmabutyrylcholinesteraseactivities
‡A
Chlorpyrifos: assessment of potential for delayed neurotoxicity by repeated dosing in adult hens with monitoring of brain acetylcholinesterase, brain and lymphocyte neurotoxic esterase, and plasma butyrylcholinesterase activities.
‡9
1
|
|
919
|
|
|
‡a
biosensordetectionofneuropathytargetesteraseinwholebloodasabiomarkerofexposuretoneuropathicorganophosphoruscompounds
‡A
Biosensor detection of neuropathy target esterase in whole blood as a biomarker of exposure to neuropathic organophosphorus compounds
‡9
1
|
|
919
|
|
|
‡a
biosensoranalysisofbloodesterasesfororganophosphoruscompoundsexposureassessmentapproachestosimultaneousdeterminationofseveralesterases
‡A
Biosensor analysis of blood esterases for organophosphorus compounds exposure assessment: approaches to simultaneous determination of several esterases
‡9
1
|
|
919
|
|
|
‡a
biomarkersofdruginducedvascularinjury
‡A
Biomarkers of drug-induced vascular injury.
‡9
1
|
|
919
|
|
|
‡a
agingofmipafoxinhibitedhumanacetylcholinesteraseproceedsbydisplacementofbothisopropylaminegroupstoyieldaphosphateadduct
‡A
Aging of mipafox-inhibited human acetylcholinesterase proceeds by displacement of both isopropylamine groups to yield a phosphate adduct.
‡9
1
|
|
919
|
|
|
‡a
absenceofsensoryneuropathyamongworkerswithoccupationalexposuretochlorpyrifos
‡A
Absence of sensory neuropathy among workers with occupational exposure to chlorpyrifos.
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
LC|n 82223657
|
|
996
|
|
|
‡2
SUDOC|030450152
|
|
996
|
|
|
‡2
SUDOC|145561542
|
|
996
|
|
|
‡2
BIBSYS|90374135
|
|
996
|
|
|
‡2
LC|no2014066452
|
|
996
|
|
|
‡2
ISNI|0000000023806606
|
|
996
|
|
|
‡2
DNB|1091592454
|
|
996
|
|
|
‡2
SUDOC|271022248
|
|
996
|
|
|
‡2
LC|n 80111201
|
|
996
|
|
|
‡2
ISNI|0000000381915167
|
|
996
|
|
|
‡2
ISNI|0000000032688517
|
|
996
|
|
|
‡2
J9U|987007378918605171
|
|
996
|
|
|
‡2
BNE|XX1008654
|
|
996
|
|
|
‡2
LC|no2017162086
|
|
996
|
|
|
‡2
NDL|00454145
|
|
996
|
|
|
‡2
NSK|000020054
|
|
996
|
|
|
‡2
SUDOC|260294500
|
|
996
|
|
|
‡2
BIBSYS|3051236
|
|
996
|
|
|
‡2
ISNI|0000000084706369
|
|
996
|
|
|
‡2
DNB|1157793304
|
|
996
|
|
|
‡2
LC|nr 96034603
|
|
996
|
|
|
‡2
SUDOC|150763638
|
|
996
|
|
|
‡2
LC|n 82208509
|
|
996
|
|
|
‡2
BIBSYS|90316676
|
|
996
|
|
|
‡2
RERO|A022909987
|
|
996
|
|
|
‡2
LC|nb2005001208
|
|
996
|
|
|
‡2
J9U|987007281484505171
|
|
996
|
|
|
‡2
RERO|A016260872
|
|
996
|
|
|
‡2
LC|nr 93033045
|
|
996
|
|
|
‡2
BIBSYS|13059018
|
|
996
|
|
|
‡2
BNCHL|10000000000000000168118
|
|
996
|
|
|
‡2
NTA|364133252
|
|
996
|
|
|
‡2
LC|nb2011011683
|
|
996
|
|
|
‡2
LC|n 94080545
|
|
996
|
|
|
‡2
CAOONL|ncf11162422
|
|
996
|
|
|
‡2
N6I|vtls000014108
|
|
996
|
|
|
‡2
DNB|1042297207
|
|
996
|
|
|
‡2
LC|n 2016066520
|
|
996
|
|
|
‡2
NTA|115536884
|
|
996
|
|
|
‡2
ISNI|0000000424502099
|
|
996
|
|
|
‡2
DNB|1057222488
|
|
996
|
|
|
‡2
CAOONL|ncf10307084
|
|
997
|
|
|
‡a
1945 0 lived 0000 0
‡9
1
|
|
998
|
|
|
‡a
Richardson, Rudy J.
‡q
(Rudy James),
‡2
J9U|987007378918605171
‡3
suggested
|
|
998
|
|
|
‡a
Richardson, Rudy James,
‡2
SUDOC|260294500
‡3
suggested
|
|
998
|
|
|
‡a
Richardson, Rudy J.
‡2
DNB|1129184250
‡3
suggested
‡3
standard number
|
|
998
|
|
|
‡a
Richardson, Rudy J.
‡q
(Rudy James),
‡2
LC|n 82208509
‡3
suggested
|
